Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 284

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 284
---
 will be eligible to: (i) annual compensation of $250, to be paid on a quarterly 
 basis; (ii) a grant of 283,532 options with an exercise price of NIS 0.01; and (iii) at a    
 Qualified IPO (as defined below), a cash payment of $500. In addition, the holdings of the   
 chairman of the Company’s board of directors shall not be diluted any lower than 9.98%       
 as a result of any IPO with a total proceeds of no less than $6,000 (a “Qualified IPO”).     |

| 3. | Increase of authorized                             
 share capital from 3,000,000 to 22,500,000 shares. |

| 4. | Cancellation of                                                          
 the Company’s nominal value per each Ordinary Share and preferred share. |

| D. | In April 2025,                                                                                 
 the Company entered into bridge loan agreements (the “April 2025 Loans” or “April              
 2025 Loan Agreements”), pursuant to which the Company obtained bridge loans from the           
 lenders thereto including certain related parties, including the Company’s chairman of the     
 board of directors, a member of the Company’s board of directors, and a director nominee.      
 The April 2025 Loans shall bear interest at 8% per annum until maturity and the Company agreed 
 to pay the lenders an additional risk premium equal to 50% of their respective loan amount.    |

The April 2025 Loan’s maturity date is
the earlier of August 31, 2025, or the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of a Qualified IPO,
the April 2025 Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective
loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares
during the first five trading days following the consummation of such IPO.

| E. | On                                                                                             
 July 1, 2025, the Company entered into amendments of the Bridge Loans, the January 2024 Loan,  
 the December 2024 Loan Agreement and the April 2025 Loan Agreements such that the lenders      
 party thereto shall be granted with a fixed number of warrants to purchase such number of      
 Ordinary Shares following the consummation of a Qualified IPO, in amounts of 140,000 warrants,